Before the trial, some participants could not eat a single milligram of peanut protein without their throats tightening and their blood pressure dropping. By the end, several of them sat in a clinic and swallowed the equivalent of a few whole peanuts with no objective reaction at all. The shift was not spontaneous. It was engineered, dose by careful dose, over months of supervised feeding in what became the first clinical trial to demonstrate oral immunotherapy desensitization specifically in adults with severe peanut allergy.
The Phase II trial, called GUPI (Grown-Up Peanut Immunotherapy), was published in the journal Allergy and has drawn renewed attention from allergists and patients heading into mid-2026. Its results arrive at a moment when roughly 4.6 million adults in the United States live with peanut allergy, according to a 2024 JACI estimate, yet the only FDA-approved peanut oral immunotherapy product, Palforzia, is licensed exclusively for children ages 4 through 17. Adults have been largely left out of both approved treatments and the clinical trials that inform them.
What the GUPI trial actually did
The protocol started small. Participants swallowed tiny, precisely measured amounts of commercially available peanut flour under direct medical supervision in a clinic. If they tolerated a dose without a significant reaction, the amount was increased at the next visit. This escalation phase stretched over weeks, with allergists on hand to treat any reaction immediately. Once a participant reached a predefined target dose, they transitioned to daily maintenance at home, continuing to eat a set quantity of store-bought peanut product every day.
That design choice is worth pausing on. Unlike Palforzia, which uses a standardized pharmaceutical-grade peanut protein powder, GUPI relied on the same peanut flour and peanut butter a person might find on a grocery shelf. The practical implication: if the approach eventually moves beyond trials, it would not depend on a single manufacturer’s supply chain or pricing. It would use food.
The immunologic logic behind the approach is well established from earlier pediatric and mixed-age trials. A foundational randomized controlled trial published in the Journal of Allergy and Clinical Immunology showed that supervised, escalating peanut doses could substantially raise the amount of protein a patient tolerated before reacting. Those trials also tracked immune markers, specifically drops in peanut-specific IgE and rises in IgG4, which researchers interpret as the immune system shifting from a hair-trigger allergic stance toward a more regulated state. Safety data from controlled studies confirmed that most reactions during escalation were mild to moderate (itchy mouth, stomach discomfort, hives), though anaphylaxis remained a real possibility, which is why every published protocol requires clinic-based dose increases with epinephrine on hand.
What made GUPI different was its exclusive focus on adults. Participants who completed the protocol moved from reacting to trace quantities of peanut protein to tolerating amounts equivalent to several whole peanuts during supervised oral food challenges. For people whose daily routines revolve around reading every ingredient label, interrogating restaurant staff, and carrying two epinephrine auto-injectors at all times, that jump in threshold represents a concrete reduction in the risk of a severe accidental reaction.
The durability problem no one has solved
Desensitization during active dosing is one outcome. Sustained tolerance after stopping therapy is a different, harder one. And so far, no adult-focused trial has achieved it.
The sharpest evidence on this point comes from the POISED study, a randomized, double-blind, placebo-controlled Phase II trial published in The Lancet in 2019. POISED found that many participants who had become desensitized while taking daily peanut doses lost their protection within weeks of stopping or substantially reducing those doses. Reaction thresholds fell back toward pre-treatment levels during follow-up food challenges. The U.S. National Institutes of Health summarized the finding plainly: peanut allergy protection was limited after oral immunotherapy ended.
The implication is uncomfortable but important. When the daily antigen signal disappears, the allergic response can reassert itself. That means desensitization, at least with the regimens tested so far, may depend on continued exposure. If true, oral immunotherapy becomes a lifelong management strategy, not a cure. Adults must weigh the burden of daily dosing (eating a food long associated with danger, scheduling clinic visits, accepting the possibility of side effects with every dose) against the benefit of a higher safety margin.
Researchers are actively trying to close that gap. At least one trial has been designed to compare high-dose and low-dose peanut oral immunotherapy regimens for their ability to produce sustained unresponsiveness after a defined period off therapy. Its durability endpoints focus on how many participants can stop dosing for weeks or months and still pass standardized peanut challenges. As of June 2026, those long-term results have not appeared in peer-reviewed publications, so it remains unknown whether higher maintenance doses, slower tapering, or other protocol adjustments can meaningfully improve durability in adults.
Safety signals that need longer follow-up
Beyond the question of whether protection lasts, there are safety concerns that grow more relevant the longer a person stays on therapy. A longitudinal, randomized study published in the Journal of Allergy and Clinical Immunology found that peanut oral immunotherapy triggered gastrointestinal eosinophil responses in some participants, raising concerns about eosinophilic esophagitis, a chronic inflammatory condition of the esophagus that can cause difficulty swallowing and food impaction. Many of these changes appeared subclinical during the study period, but whether they resolve after therapy ends or progress into symptomatic disease over years of daily dosing has not been clearly established in adult-only datasets.
Some researchers have explored whether adding the anti-IgE biologic omalizumab can reduce the risk and discomfort of the escalation phase. An uncontrolled clinical study in adults combined omalizumab with peanut oral immunotherapy and reported that the drug appeared to facilitate faster dose increases with fewer interruptions. An earlier study in highly allergic patients found similar results. These findings have encouraged some centers to explore biologic-assisted protocols for adults who would otherwise be considered too high-risk for standard escalation. But because neither study included a comparison group receiving peanut oral immunotherapy alone, the added benefit of omalizumab cannot be isolated from the effect of the dosing protocol itself.
Practical adherence is another open question. Most published trials report outcomes at or shortly after the end of the protocol. There is little data on how many adults continue daily dosing months or years later, or how they integrate the regimen into work, travel, and family life. Some participants in published accounts describe anxiety around every dose, knowing it could provoke symptoms. Others report relief at the higher threshold and accept the trade-off. Without robust long-term adherence and patient-reported outcome data, it is difficult to predict how oral immunotherapy will function outside specialized research centers.
What this means for adults with peanut allergy right now
The strongest evidence in this space comes from randomized, controlled trials with blinded comparisons and defined endpoints. The POISED study and the foundational RCT of peanut oral immunotherapy both meet that standard. The GUPI trial, while offering the most directly relevant adult data, is a Phase II study without a placebo arm. Its open-label design makes it harder to separate true treatment effects from expectation or behavioral changes, and its relatively small sample size limits how confidently results can be generalized.
For adults living with severe peanut allergy, the practical picture as of mid-2026 is cautious but genuinely hopeful. Clinic-supervised oral immunotherapy can raise reaction thresholds during active treatment, which could reduce the risk of a severe or fatal accidental exposure and may ease some of the relentless daily vigilance around cross-contact. But no published adult-focused trial has yet demonstrated that therapy can be stopped entirely while preserving protection over the long term.
Every published protocol requires medical supervision during dose escalation, and adverse reactions, while mostly mild, can include anaphylaxis that demands immediate treatment. No version of this therapy is appropriate as a self-directed experiment using store-bought peanuts without professional guidance. Adults interested in pursuing this option can search for active clinical trials through ClinicalTrials.gov, review eligibility criteria, and discuss potential enrollment with a board-certified allergist who specializes in food allergy immunotherapy. The usual first step is a formal oral food challenge in a controlled setting, which confirms the diagnosis, defines the current reaction threshold, and helps the care team decide whether a structured desensitization protocol is a reasonable next move. For now, the science says the immune system can be retrained. The question still being answered is whether it stays retrained once you stop teaching it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
